Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy
Tài liệu tham khảo
Wang, 2020, CAR-NK for tumor immunotherapy: clinical transformation and future prospects, Cancer Lett., 472, 175, 10.1016/j.canlet.2019.11.033
Nam, 2019, Cancer nanomedicine for combination cancer immunotherapy, Nat. Rev. Mater., 4, 398, 10.1038/s41578-019-0108-1
Xu, 2020, A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy, Nat. Nanotechnol., 15, 1043, 10.1038/s41565-020-00781-4
Hodi, 2010, Improved survival with Ipilimumab in patients with metastatic melanoma, N. Engl. J. Med., 363, 711, 10.1056/NEJMoa1003466
Formenti, 2018, Radiotherapy induces responses of lung cancer to CTLA-4 blockade, Nat. Med., 24, 1845, 10.1038/s41591-018-0232-2
Duruisseaux, 2018, Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis, Lancet Respir. Med., 6, 771, 10.1016/S2213-2600(18)30284-4
Beaver, 2018, Patients with melanoma treated with an anti-PD-1 antibody beyond recist progression: a US food and drug administration pooled analysis, Lancet Oncol., 19, 229, 10.1016/S1470-2045(17)30846-X
Xu, 2019, Anti-PD-1 antibody SHR-1210 combined with Apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study, Clin. Cancer Res., 25, 515, 10.1158/1078-0432.CCR-18-2484
Kowanetz, 2018, Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1), Proc. Natl. Acad. Sci. U. S. A., 115, E10119, 10.1073/pnas.1802166115
Emens, 2019, Long-term clinical outcomes and biomarker analyses of Atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study, JAMA Oncol., 5, 74, 10.1001/jamaoncol.2018.4224
Sharma, 2019, Anti-CTLA-4 immunotherapy does not deplete FoxP3(+) regulatory T cells (Tregs) in human cancers, Clin. Cancer Res., 25, 1233, 10.1158/1078-0432.CCR-18-0762
Sabet, 2016, Severe acute pulmonary toxicity associated with brentuximab in a patient with refractory hodgkin’s lymphoma, Case Rep. Pulmonol., 2016
Younes, 2016, Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial, Lancet Oncol., 17, 1283, 10.1016/S1470-2045(16)30167-X
Collins, 2019, A failure to start: aborted activation of CAR T cells in chronic lymphocytic leukemia, Blood, 134, 10.1182/blood-2019-122063
Mahony, 2007, A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy, Clin. Cancer Res., 13, 958, 10.1158/1078-0432.CCR-06-1974
Kim, 2017, Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas, Clin. Cancer Res., 23, 124, 10.1158/1078-0432.CCR-15-1535
Dewan, 2009, Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti–CTLA-4 antibody, Clin. Cancer Res., 15, 5379, 10.1158/1078-0432.CCR-09-0265
Nie, 2019, Addition of low-dose decitabine to anti–PD-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma, J. Clin. Oncol., 37, 1479, 10.1200/JCO.18.02151
Wang, 2014, Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis, Adv. Mater., 26, 8154, 10.1002/adma.201402996
Corrales, 2016, The host STING pathway at the interface of cancer and immunity, J. Clin. Invest., 126, 2404, 10.1172/JCI86892
Su, 2019, STING activation in cancer immunotherapy, Theranostics, 9, 7759, 10.7150/thno.37574
Corrales, 2015, Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity, Cell Rep., 11, 1018, 10.1016/j.celrep.2015.04.031
Foote, 2017, A STING agonist given with OX40 receptor and PD-L1 modulators primes immunity and reduces tumor growth in tolerized mice, Cancer Immunol. Res., 5, 468, 10.1158/2326-6066.CIR-16-0284
Sivick, 2019, Magnitude of therapeutic STING activation determines CD8+ T cell-mediated anti-tumor immunity, Cell Rep., 29, 785, 10.1016/j.celrep.2019.09.089
Junkins, 2018, A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination, J. Contr. Release, 270, 1, 10.1016/j.jconrel.2017.11.030
Amouzegar, 2021, STING agonists as cancer therapeutics, Cancers, 13, 1, 10.3390/cancers13112695
Leach, 2018, STINGel: controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy, Biomaterials, 163, 67, 10.1016/j.biomaterials.2018.01.035
Munoz, 2021, Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy, J. Immunother. Cancer, 9, 10.1136/jitc-2020-001800
Lu, 2020, Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy, Sci. Transl. Med., 12, 10.1126/scitranslmed.aaz6606
An, 2018, Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity, Nanoscale, 10, 9311, 10.1039/C8NR01376D
Koshy, 2017, Liposomal delivery enhances immune activation by STING agonists for cancer immunotherapy, Adv. Biosyst, 1, 10.1002/adbi.201600013
Cheng, 2018, A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer, JCI Insight, 3, 3, 10.1172/jci.insight.120638
Wehbe, 2021, Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration, J. Contr. Release, 330, 1118, 10.1016/j.jconrel.2020.11.017
Shae, 2019, Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy, Nat. Nanotechnol., 14, 269, 10.1038/s41565-018-0342-5
Jiang, 2018, Protein toxin chaperoned by LRP-1-targeted virus-mimicking vesicles induces high-efficiency glioblastoma therapy in vivo, Adv. Mater., 30, 10.1002/adma.201800316
Yang, 2018, Granzyme B-loaded, cell-selective penetrating and reduction-responsive polymersomes effectively inhibit progression of orthotopic human lung tumor in vivo, J. Contr. Release, 290, 141, 10.1016/j.jconrel.2018.10.013
Zou, 2017, Virus-mimicking chimaeric polymersomes boost targeted cancer siRNA therapy in vivo, Adv. Mater., 29, 10.1002/adma.201703285
Lhuillier, 2019, Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system, Genome Med., 11, 2, 10.1186/s13073-019-0653-7
Galluzzi, 2016, Immunogenic cell death in cancer and infectious disease, Nat. Rev. Immunol., 17, 97, 10.1038/nri.2016.107
Uribe-Herranz, 2020, Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response, J. Clin. Invest., 130, 466, 10.1172/JCI124332
Deng, 2016, From DNA damage to nucleic acid sensing: a strategy to enhance radiation therapy, Clin. Cancer Res., 22, 20, 10.1158/1078-0432.CCR-14-3110
Mullard, 2018, Can innate immune system targets turn up the heat on 'cold' tumours?, Nat. Rev. Drug Discov., 17, 3, 10.1038/nrd.2017.264
Vrignaud, 2011, Strategies for the nanoencapsulation of hydrophilic molecules in polymer-based nanoparticles, Biomaterials, 32, 8593, 10.1016/j.biomaterials.2011.07.057
Shi, 2018, Boosting RNAi therapy for orthotopic glioblastoma with nontoxic brain-targeting chimaeric polymersomes, J. Contr. Release, 292, 163, 10.1016/j.jconrel.2018.10.034
Xia, 2021, Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CPG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma, J. Contr. Release, 336, 262, 10.1016/j.jconrel.2021.06.032
Lee, 2016, Submicron-sized hydrogels incorporating cyclic dinucleotides for selective delivery and elevated cytokine release in macrophages, Acta Biomater., 29, 271, 10.1016/j.actbio.2015.10.025
Baird, 2016, Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors, Cancer Res., 76, 50, 10.1158/0008-5472.CAN-14-3619
Wang, 2017, cGAS is essential for the antitumor effect of immune checkpoint blockade, P. Natl. Acad. Sci. USA, 114, 1637, 10.1073/pnas.1621363114
Motwani, 2019, DNA sensing by the cGAS–STING pathway in health and disease, Nat. Rev. Genet., 20, 657, 10.1038/s41576-019-0151-1
Veglia, 2017, Dendritic cells in cancer: the role revisited, Curr. Opin. Immunol., 45, 43, 10.1016/j.coi.2017.01.002
Liu, 2015, Intratumoral dendritic cells in the anti-tumor immune response, Cell. Mol. Immunol., 12, 387, 10.1038/cmi.2014.130
Li, 2018, A facile approach to enhance antigen response for personalized cancer vaccination, Nat. Mater., 17, 528, 10.1038/s41563-018-0028-2
Yang, 2019, Functional T cell activation by smart nanosystems for effective cancer immunotherapy, Nano, Today Off., 27, 28
Flood, 2019, STING pathway agonism as a cancer therapeutic, Immunol. Rev., 290, 24, 10.1111/imr.12765
Li, 2018, The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer, J. Exp. Med., 215, 1287, 10.1084/jem.20180139
Shang, 2019, Cryo-em structures of STING reveal its mechanism of activation by cyclic GMP-AMP, Nature, 567, 389, 10.1038/s41586-019-0998-5
Cabral, 2011, Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size, Nat. Nanotechnol., 6, 815, 10.1038/nnano.2011.166
Zhang, 2018, Rational design of nanoparticles with deep tumor penetration for effective treatment of tumor metastasis, Adv. Funct. Mater., 28
Ahn, 2018, Extrinsic phagocyte-dependent STING signaling dictates the immunogenicity of dying cells, Cancer Cell, 33, 862, 10.1016/j.ccell.2018.03.027
Ahmed, 2016, Current insights in radiation combination therapies: influence of omics and novel targeted agents in defining new concepts in radiation biology and clinical radiation oncology, Semin. Radiat. Oncol., 26, 251, 10.1016/j.semradonc.2016.07.002
Liu, 2019, An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases, Nat. Commun., 10, 10.1038/s41467-019-13094-5
Deng, 2014, STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors, Immunity, 41, 843, 10.1016/j.immuni.2014.10.019
Schudel, 2019, Material design for lymph node drug delivery, Nat. Rev. Mater., 4, 415, 10.1038/s41578-019-0110-7
Chang, 2018, Irradiation enhances abscopal anti-tumor effects of antigen-specific immunotherapy through regulating tumor microenvironment, Mol. Ther., 26, 404, 10.1016/j.ymthe.2017.11.011
Li, 2019, Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy, J. Hematol. Oncol., 12, 10.1186/s13045-019-0721-x
Snell, 2017, Type I interferon in chronic virus infection and cancer, Trends Immunol., 38, 542, 10.1016/j.it.2017.05.005
Mitchell, 2021, Engineering precision nanoparticles for drug delivery, Nat. Rev. Drug Discov., 20, 101, 10.1038/s41573-020-0090-8
Ding, 2019, Engineered nanomedicines with enhanced tumor penetration, Nano Today, 29, 10.1016/j.nantod.2019.100800